Urogen Pharma (URGN) Competitors $18.95 +0.95 (+5.26%) As of 03:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. RARE, AMRX, CPRX, GMTX, OGN, ARWR, APLS, XENE, IBRX, and NAMSShould you be buying Urogen Pharma stock or one of its competitors? The main competitors of Urogen Pharma include Ultragenyx Pharmaceutical (RARE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Organon & Co. (OGN), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Urogen Pharma vs. Its Competitors Ultragenyx Pharmaceutical Amneal Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Organon & Co. Arrowhead Pharmaceuticals Apellis Pharmaceuticals Xenon Pharmaceuticals ImmunityBio NewAmsterdam Pharma Ultragenyx Pharmaceutical (NASDAQ:RARE) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Does the media refer more to RARE or URGN? In the previous week, Urogen Pharma had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 10 mentions for Urogen Pharma and 7 mentions for Ultragenyx Pharmaceutical. Urogen Pharma's average media sentiment score of 0.64 beat Ultragenyx Pharmaceutical's score of -0.21 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Urogen Pharma 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, RARE or URGN? Ultragenyx Pharmaceutical has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Do institutionals & insiders believe in RARE or URGN? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 5.1% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate RARE or URGN? Ultragenyx Pharmaceutical presently has a consensus target price of $83.64, suggesting a potential upside of 204.37%. Urogen Pharma has a consensus target price of $32.86, suggesting a potential upside of 73.43%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, RARE or URGN? Urogen Pharma has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Urogen Pharma is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$590.69M4.40-$569.18M-$5.88-4.67Urogen Pharma$91.87M9.53-$126.87M-$3.18-5.96 Is RARE or URGN more profitable? Ultragenyx Pharmaceutical has a net margin of -93.04% compared to Urogen Pharma's net margin of -150.68%. Ultragenyx Pharmaceutical's return on equity of -186.49% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-93.04% -186.49% -36.81% Urogen Pharma -150.68%-97,487.15%-49.57% SummaryUltragenyx Pharmaceutical beats Urogen Pharma on 9 of the 17 factors compared between the two stocks. Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUrogen PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$876.20M$3.04B$5.72B$9.52BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-5.9621.1228.0720.02Price / Sales9.53340.60462.58104.32Price / CashN/A43.2336.5558.97Price / Book-90.228.338.645.90Net Income-$126.87M-$55.19M$3.24B$258.50M7 Day Performance24.07%5.91%4.08%2.12%1 Month Performance38.09%17.69%10.68%12.62%1 Year Performance15.81%5.36%34.47%19.25% Urogen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUrogen Pharma4.5082 of 5 stars$18.95+5.3%$32.86+73.4%+10.0%$876.20M$91.87M-5.96200RAREUltragenyx Pharmaceutical4.35 of 5 stars$27.17-0.1%$83.64+207.9%-39.5%$2.57B$590.69M-4.631,294Upcoming EarningsGap DownAMRXAmneal Pharmaceuticals3.1369 of 5 stars$8.13-1.7%$11.60+42.6%+8.0%$2.55B$2.83B-203.258,100CPRXCatalyst Pharmaceuticals4.9232 of 5 stars$20.72-1.1%$32.83+58.5%+20.0%$2.53B$534.65M13.2080News CoveragePositive NewsAnalyst RevisionGMTXGemini TherapeuticsN/A$57.74+1.5%N/A+32.1%$2.50BN/A-57.7430OGNOrganon & Co.4.7681 of 5 stars$9.57+0.1%$18.00+88.2%-53.5%$2.49B$6.40B3.334,000ARWRArrowhead Pharmaceuticals3.782 of 5 stars$17.89+1.4%$43.71+144.4%-43.8%$2.47B$3.55M-12.78400News CoveragePositive NewsAPLSApellis Pharmaceuticals4.2298 of 5 stars$19.43+0.4%$39.84+105.0%-46.3%$2.46B$775.84M-10.92770Upcoming EarningsXENEXenon Pharmaceuticals3.7513 of 5 stars$31.42-0.2%$54.82+74.5%-29.1%$2.42B$7.50M-9.77210Positive NewsOptions VolumeIBRXImmunityBio2.1548 of 5 stars$2.73-0.5%$12.25+349.5%-43.5%$2.41B$14.74M-4.70590News CoverageAnalyst ForecastNAMSNewAmsterdam Pharma3.7852 of 5 stars$21.03+0.0%$42.89+104.0%+23.8%$2.36B$45.56M-11.184 Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors Amneal Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Gemini Therapeutics Competitors Organon & Co. Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors ImmunityBio Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
